Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.04% | 6.72% | 0.85% | 34.80% | 1.09% |
| Total Depreciation and Amortization | -3.07% | -39.29% | -0.88% | -29.17% | -1.07% |
| Total Amortization of Deferred Charges | -3.00% | -- | -- | -- | -1.04% |
| Total Other Non-Cash Items | 3.03% | -539.52% | -0.94% | -88.38% | -1.08% |
| Change in Net Operating Assets | 3.13% | -126.69% | 1.00% | 98.08% | 1.09% |
| Cash from Operations | 3.04% | -2.79% | 0.85% | 58.45% | 1.09% |
| Capital Expenditure | -- | -- | -- | -- | 1.10% |
| Sale of Property, Plant, and Equipment | -2.44% | -- | -- | -- | -0.71% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 0.78% | -12,700.00% | 0.00% |
| Cash from Investing | -2.44% | 112.91% | 0.78% | 78.70% | 1.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -1.20% | 0.00% | -56.60% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -60.50% | 0.00% | 11,190.00% | 0.00% |
| Cash from Financing | -3.02% | -62.06% | -0.86% | -76.81% | -1.09% |
| Foreign Exchange rate Adjustments | 4.55% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -16.67% | 220.00% | 0.00% | -- | -- |
| Net Change in Cash | 3.04% | -167.39% | 0.86% | -138.54% | -1.09% |